scholarly journals Cellular uptake and catabolism of high-density-lipoprotein triacylglycerols in human cultured fibroblasts: degradation block in neutral lipid storage disease

1994 ◽  
Vol 297 (3) ◽  
pp. 467-473 ◽  
Author(s):  
N Hilaire ◽  
A Nègre-Salvayre ◽  
R Salvayre

High-density lipoprotein (HDL)-[3H]triolein (i.e. [3H]triolein incorporated into reconstituted HDL) was taken up by cultured fibroblasts through an apparently saturable process, competitively inhibited by non-labelled HDL and independent of the LDL receptor. Using 125I-HDL and HDL-[3H]triolein, binding experiments (at 0 degrees C) followed by a short-time ‘chase’ at 37 degrees C showed that 125I radioactivity was rapidly released in the culture medium (as trichloroacetic acid-precipitable material), whereas 3H radioactivity remained associated with the cell. The cell-associated HDL-[3H]triolein was rapidly degraded in normal fibroblasts, and the liberated [3H]oleic acid was incorporated into newly biosynthesized phospholipids. In Wolman-disease fibroblasts HDL-[3H]triolein was degraded at a normal rate, and thus independently of the lysosomal compartment. In contrast, the degradation of HDL-[3H]triolein was blocked in fibroblasts from Neutral Lipid Storage Disease (NLSD), similarly to that of endogenously biosynthesized triacylglycerols [Radom, Salvayre, Nègre, Maret and Douste-Blazy (1987) Eur. J. Biochem. 164, 703-708]. Trypsin-treated HDL-[3H]triolein was also taken up by cells and degraded quite similarly to HDL-[3H]triolein. In conclusion, all these data taken together suggest that HDL-[3H]triolein is: (i) associated with the cell through a process independent of intact apolipoprotein (apo) As, thus probably independent of an apoA-receptor-mediated uptake; (ii) internalized by cells, whereas 125I-apoAs are released in the culture medium; (iii) directed to the same non-lysosomal catabolic pool (blocked in NLSD) as for endogenously biosynthesized triacylglycerols.

2018 ◽  
Vol 28 (7) ◽  
pp. 606-609 ◽  
Author(s):  
Caitlin S. Latimer ◽  
Jennifer Schleit ◽  
Adam Reynolds ◽  
Desiree A. Marshall ◽  
Benjamin Podemski ◽  
...  

2020 ◽  
Vol 83 (3) ◽  
pp. 317-322
Author(s):  
Makoto Samukawa ◽  
Naoko Nakamura ◽  
Makito Hirano ◽  
Miyuki Morikawa ◽  
Hanami Sakata ◽  
...  

Mutations in the PNPLA2 gene cause neutral lipid storage disease with myopathy (NLSDM) or triglyceride deposit cardiomyovasculopathy. We report a detailed case study of a 53-year-old man with NLSDM. The PNPLA2 gene was analyzed according to the reported method. We summarized the clinical, laboratory, and genetic information of 56 patients, including our patient and 55 other reported patients with homozygous or compound heterozygous mutations in the PNPLA2 gene. We found a novel homozygous mutation (c.194delC) in the PNPLA2 gene that resulted in frameshift. The patient suffered from normal-tension glaucoma and pulmonary cysts, symptoms that are relatively common in the elderly but were not previously reported for this disease. Our summary confirmed that Jordan’s anomaly, polymorphonuclear leukocytes with lipid accumulation, was the most consistent finding of this disease. Because this disease is potentially treatable, our results may help rapid and correct diagnosis.


1994 ◽  
Vol 153 (3) ◽  
pp. 210-211 ◽  
Author(s):  
A. Dursun ◽  
A. Kubar ◽  
A. Gokoz ◽  
F. Duru ◽  
A. Gürgey

2016 ◽  
Vol 53 (4) ◽  
pp. 644-648 ◽  
Author(s):  
Roberto Massa ◽  
Simone Pozzessere ◽  
Emanuele Rastelli ◽  
Laura Serra ◽  
Chiara Terracciano ◽  
...  

1988 ◽  
Vol 11 (2) ◽  
pp. 131-143 ◽  
Author(s):  
M. L. Williams ◽  
D. J. Monger ◽  
S. L. Rutherford ◽  
M. Hincenbergs ◽  
S. J. Rehfeld ◽  
...  

1994 ◽  
Vol 19 (5) ◽  
pp. 434-437 ◽  
Author(s):  
J. BANULS ◽  
I. BETLLOCH ◽  
R. BOTELLA ◽  
A. SEVILA ◽  
A. MORELL ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document